# Open-Label, Long-Term Treatment Study, to Assess the Long-Term Safety and Tolerability and Efficacy of Neramexane in Patients With Subjective Tinnitus

> **NCT00827008** · PHASE3 · TERMINATED · sponsor: **Merz Pharmaceuticals GmbH** · enrollment: 821 (actual)

## Conditions studied

- Subjective Tinnitus

## Interventions

- **DRUG:** Neramexane mesylate

## Key facts

- **NCT ID:** NCT00827008
- **Lead sponsor:** Merz Pharmaceuticals GmbH
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2009-01
- **Primary completion:** 2011-12
- **Final completion:** 2011-12
- **Target enrollment:** 821 (ACTUAL)
- **Last updated:** 2012-11-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00827008

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00827008, "Open-Label, Long-Term Treatment Study, to Assess the Long-Term Safety and Tolerability and Efficacy of Neramexane in Patients With Subjective Tinnitus". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT00827008. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*